|
Investigation of Abiomed Marketing Practices Shadows Strong Quarter
Cardiac devicemaker Abiomed is under scrutiny for its marketing and labeling of the Impella 2.5 heart pump, the company said in a Nov. 1 earnings statement covering the second quarter of fiscal 2013.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives